istock-510070258_rawpixel

rawpixel / iStockphoto.com

10 November 2017Big Pharma

LSIPR 50 2017: Thomas Kirkbak—Communication is key

IP infringement covering pharmaceuticals typically takes place where generic companies can make the most profits, according to Thomas Kirkbak, chief IP litigation specialist and attorney-at-law at Lundbeck.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Teva fights for re-listing of inhaler patents at US appeals court

White & Case hires experienced litigator from A&O Shearman

China’s new policies on foreign investment in healthcare and biotech

Startup CFO’s betrayal is a lesson in preparing for the worst

Sandoz lands reduced antitrust award of $70m

Teva faces $500m fine for antitrust breaches over MS drug

UK Budget: A missed opportunity?

Pfizer infringed haemophilia therapy patent, says court